Medicare AdvantageCoverageMedium impact
MA07.008e, Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions
Independence Blue Cross·Orthopedics, Wound Care, General Surgery +2 more·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.008e regarding stem-cell therapy and platelet-rich plasma treatments for orthopedic and wound healing applications has been reissued and will take effect March 5, 2025. This policy update affects coverage determinations and billing requirements for these specialized treatments.
Action Required
Before March 5, 2025: Billing team must review the complete MA07.008e policy document to identify specific coverage criteria and billing requirements for stem-cell therapy and platelet-rich plasma procedures. Update billing workflows and prior authorization processes for Medicare Advantage patients receiving these treatments. Ensure providers understand any new documentation requirements for orthopedic and wound healing applications.